An oral drug delivery system for treatment of tuberculosis is described. The oral drug delivery system includes (e.g., a mixture or combination of): poly DL-lactide-co-glycolide nano particles having encapsulated an azole therein poly DL-lactide-co-glycolide nano particles having moxifloxacin encapsulated therein and poly DL-lactide-co-glycolide nano particles having RIF encapsulated therein.
